Drugs / Brachyury-TRICOM
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04296942 | May → Oct 2021 | HER2 positive breast carcinoma, triple-negative breast carcinoma | National Cancer Institute (NCI) | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Brachyury-TRICOM | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04296942 ↗ |
| Known as | fowlpox virus (FPV)-Brachyury | “Recombinant fowlpox virus (FPV)-Brachyury: 1 injection given SC in one extremity on Day 1 of Cycles 3 and beyond.” NCT04296942 ↗ |
| Modality | Vaccine | “It is 2 different vaccines - a prime and a boost.” NCT04296942 ↗ |
| Route | Subcutaneous | “1 injection given SC in one extremity on Day 1 of Cycles 3 and beyond.” NCT04296942 ↗ |